Low high-density lipoprotein cholesterol and low/normal body mass index are associated with increased mortality in coronary artery disease patients in Taiwan

Circulation Journal

Volumn 77, Issue 8, 2013, Pages 2079-2087

  Lin, Gen Min ^a,b   Li, Yi Hwei ^a   Lin, Chin Lon ^c   Wang, Ji Hung ^c   Han, Chih Lu ^c,d  

^a TZU CHI UNIVERSITY   (Taiwan)

^b HUALIEN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

All cause mortality; Angiography; Body mass index; Coronary artery disease; High density lipoprotein cholesterol

Indexed keywords

CREATININE; DIURETIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEOPLASM; OBESITY; TAIWAN;

AGED; BODY MASS INDEX; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; TIME FACTORS;

EID: 84880773738     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1511     Document Type: Article

References (38)

1. Maron DJ. The epidemiology of low levels of high-density lipopro-tein cholesterol in patients with and without coronary artery disease. Am J Cardiol 2000; 86(Suppl): 11L-14L.
2. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 1995; 76: 69C-77C.
3. Ballantyne CM, Herd JA, Ferlic LL, Dunn JK, Farmer JA, Jones PH, et al. Infuence of low HDL on progression of coronary artery disease and response to fuvastatin therapy. Circulation 1999; 99: 736-743.
4. Okuyama H, Hamazaki T, Ogushi Y; Committee on Cholesterol Guidelines for Longevity, the Japan Society for Lipid Nutrition. New Cholesterol Guidelines for Longevity (2010). World Rev Nutr Diet 2011; 102: 124-136.
5. Cheung MC, Brown BG, Wolf AC, Albers JJ. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J Lipid Res 1991; 32: 383-394.
6. Angerås O, Albertsson P, Karason K, Råmunddal T, Matejka G, James S, et al. Evidence for obesity paradox in patients with acute coronary syndromes: A report from the Swedish Coronary Angiography and Angioplasty Registry. Eur Heart J 2013; 34: 345-353.
7. Lin GM, Li YH, Zheng NC, Lai CP, Lin CL, Wang JH, et al. Serum uric acid as an independent predictor of mortality in high-risk patients with obstructive coronary artery disease: A prospective observational cohort study from the ET-CHD registry, 1997-2003. J Cardiol 2013; 61: 122-127.
8. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988; 78: 1157-1166.
9. Expert Panel on the Identifcation, Evaluation, and Treatment of Overweight in Adults. Clinical guidelines on the identifcation, evaluation, and treatment of overweight and obesity in adults: Executive summary. Am J Clin Nutr 1998; 68: 899-917.
10. Lin GM, Li YH, Lin CL, Wang JH, Han CL. Relation of body mass index to mortality among Asian patients with obstructive coronary artery disease during a 10-year follow-up: A report from ET-CHD registry. Int J Cardiol 2013 February 25, doi:10.1016/j.ijcard.2013. 01.204 [Epub ahead of print].
11. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality: The Framingham Heart Study. Arterioscler Thromb Vasc Biol 1988; 8: 737-741.
12. AIM-HIGH Investigators, Boden WE, Probstfeld JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-2267.
13. Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361: 2113-2122.
14. Barter PJ, Rye KA, Tardif JC, Waters DD, Boekholdt SM, Breazna A, et al. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation 2011; 124: 555-562.
15. Lüscher TF, Taddei S, Kaski JC, Jukema JW, Kallend D, Münzel T, et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: The dal-VESSEL randomized clinical trial. Eur Heart J 2012; 33: 857-865.
16. Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: A randomized controlled trial. JAMA 2011; 306: 2099-2109.
17. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, et al; Determining the Effcacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363: 2406-2415.
18. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367: 2089-2099.
19. Duivenvoorden R, Fayad ZA. Safety of CETP inhibition. Curr Opin Lipidol 2012; 23: 518-524.
20. Rader DJ, Tall AR. The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? Nat Med 2012; 18: 1344-1346.
21. Naik SU, Wang X, Da Silva JS, Jaye M, Macphee CH, Reilly MP, et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 2006; 113: 90-97.
22. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003; 290: 2292-2300.
23. Imaizumi S, Navab M, Morgantini C, Charles-Schoeman C, Su F, Gao F, et al. Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins. Circ J 2011; 75: 1533-1538.
24. Tian L, Jia L, Mingde F, Tian Y, Xu Y, Tian H, et al. Alterations of high density lipoprotein subclasses in obese subjects. Lipids 2006; 41: 789-796.
25. Kalantar-Zadeh K, Block G, Howich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004; 43: 1439-1444.
26. Lin GM, Chu KM, Han CL. Reverse epidemiology refects C-reac-tive protein as a bystander of atherosclerosis in established systemic infammation models. Int J Cardiol 2011; 146: 422-423.
27. Carnethon MR, De Chavez PJ, Biggs ML, Lewis CE, Pankow JS, Bertoni AG, et al. Association of weight status with mortality in adults with incident diabetes. JAMA 2012; 308: 581-590.
28. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005; 81: 543-554.
29. Lee K. Metabolically obese but normal weight (MONW) and meta-bolically healthy but obese (MHO) phenotypes in Koreans: Characteristics and health behaviors. Asia Pac J Clin Nutr 2009; 18: 280-284.
30. Florez H, Castillo-Florez S. Beyond the obesity paradox in diabetes: Fitness, fatness, and mortality. JAMA 2012; 308: 619-620.
31. Ostfeld R, Mookherjee D, Spinelli M, Holtzman D, Shoyeb A, Schaefer M, et al. A triglyceride/high-density lipoprotein ratio > or = 3.5 is associated with an increased burden of coronary artery disease on cardiac catheterization. J Cardiometab Syndr 2006; 1: 13-15.
32. Matsumoto I, Miyake Y, Mizukawa M, Takagi Y. Impact of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio on long-term outcome in patients undergoing percutaneous coronary intervention. Circ J 2011; 75: 905-910.
33. Tanaka S, Sakata R, Marui A, Furukawa Y, Kita T, Kimura T; CREDO-Kyoto Investigators. Predicting long-term mortality after frst coronary revascularization: The Kyoto model. Circ J 2012; 76: 328-334.
34. Charach G, George J, Roth A, Rogowski O, Wexler D, Sheps D, et al. Baseline low-density lipoprotein cholesterol levels and outcome in patients with heart failure. Am J Cardiol 2010; 105: 100-104.
35. Araújo JP, Friões F, Azevedo A, Lourenço P, Rocha-Gonçalves F, Ferreira A, et al. Cholesterol: A marker of nutritional status in mild to moderate heart failure. Int J Cardiol 2008; 129: 65-68.
36. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, et al. Association between cholesterol level and mortality in dialysis patients: Role of infammation and malnutrition. JAMA 2004; 29: 451-459.
37. Noda H, Iso H, Irie F, Sairenchi T, Ohtaka E, Ohta H. Gender difference of association between LDL cholesterol concentrations and mortality from coronary heart disease amongst Japanese: The Ibaraki Prefectural Health Study. J Intern Med 2010; 267: 576-587.
38. Ogushi Y, Hamazaki T, Kirihara Y. Blood cholesterol as a good marker of health in Japan. World Rev Nutr Diet 2009; 100: 63-70.